eTheRNA Advances mRNA-Based Melanoma Immunotherapy ECI-006

0
eTheRNA immunotherapies plans to advance its mRNA-based immunotherapy candidate for melanoma, ECI-006, to a Phase I/II trial in the third quarter of this year following positive first-in-human data showing immune response in 35% of patients in an adjuvant setting, CEO Steven Powell, PhD, told GEN. [NHS]

eTheRNA immunotherapies plans to advance ECI-006 to a Phase I/II trial in the third quarter of this year following positive first-in-human data showing immune response in 35% of patients in an adjuvant setting . . .

Get GEN Edge Today!